Institute for Translational Medicine and Pharmacology at Mount Sinai

It has been an honor to launch the Institute for Translational Medicine and Pharmacology at Mount Sinai. Our vision is to translate discoveries in basic science into innovative therapeutics and clinical interventions for advancing the quality of medical care.

Our institute comprises 10 research programs, spanning the fields of endocrinology, neuroscience, immunology, cardio-pulmonary sciences, nephrology, and psychiatry. The list continues to grow. Members use advanced technologies to discover and investigate the biology of actionable molecular targets and create drugs for a variety of human disorders. Our research, funded primarily by the National institutes of Health and other funding agencies, is supported by our CoREs. These enable phenotyping, neurobehavioral studies, and biopharmaceutical development, among other capabilities. Our translational studies follow criteria for Good Laboratory Practices for pre-clinical studies allowing experiments performed in our academic setting to meet the regulatory threshold for Investigational New Drug filings towards early phase clinical trials. Further, our research programs are well positioned to use the resources, patient populations, and culture of innovation and collaboration available within a top-tier academic medical center.

Finally, and importantly, we currently train young scientists to tackle obesity, osteoporosis, disorders of cognition, myeloproliferative neoplasms, sickle cell disease, rheumatoid arthritis, and neuropsychiatric conditions in a highly interactive and interdisciplinary environment. Mentorship of our next generation of translational research scientists is of paramount importance to our mission.

Mone Zaidi, MD, PhD, MBA, MACP, FRCP, DSc (h.c.), ScD (h.c.)
Mount Sinai Professor of Clinical Medicine
Director, Institute for Translational Medicine and Pharmacology at Mount Sinai